Investor Relations

Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

View all »   RSSRecent Releases

Jun 2, 2017
Arbutus to Participate in Upcoming Investor Conferences

May 22, 2017
Arbutus Presents HBV Drug Combination Studies at ICAR

View all »Events & Presentations

Jun 20, 2017
JMP Securities Life Sciences Conference

Jun 6, 2017
Jefferies 2017 Global Healthcare Conference